Astellas Pharma Gmbh

Tatsuya Zenkoh

Hiroshi Matsuda

Ryushi Seo

Yoshimasa Imamura

Eisuke Nozawa

Keisuke Matsuura

Junji Sato

Hiroshi Nagata

Norio Seki

Jun Maeda

Minoru Yasuda

Junko Watanabe

Tadashi Terasaka

Kazuhiro Ikegai

Susumu Watanuki

Yoshiyuki Tenda

Masahiro Takeda

Hiroki Fukudome

Michihito Kageyama

Nobuaki Takeshita

Ryotaro Ibuka

Seiichiro Tabuchi

Hiroshi Inami

Takeshi Terasawa

Hisashi Hayashida

Mamoru Tasaki

Kazunori Tsubaki

Kouzo Sawada

Satoru Kuroda

[Problems] A compound, which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy, is provided. [Solving Means] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic activity, and confirmed that the amide compound of the present invention has an EP4 receptor antagonistic activity, thereby completing the present invention. The amide compound of the present invention has an EP4 receptor antagonistic activity, and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating various EP4-related diseases, for example, chronic renal failure and/or diabetic nephropathy, and the like.

Amide compound

The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents

This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.

Amide derivatives as rock inhibitors

Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.

Ornithine derivative

Growing community of inventors

Tokyo, Japan

Tatsuya Zenkoh